{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:33:51Z","timestamp":1792164831271,"version":"4.4.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2001,11,1]],"date-time":"2001-11-01T00:00:00Z","timestamp":1004572800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2001,11]]},"DOI":"10.1007\/s11940-001-0011-z","type":"journal-article","created":{"date-parts":[[2007,6,4]],"date-time":"2007-06-04T18:14:20Z","timestamp":1180980860000},"page":"479-493","source":"Crossref","is-referenced-by-count":8,"title":["Parkinson\u2019s disease: Initial treatment with levodopa or dopamine agonists"],"prefix":"10.1007","volume":"3","author":[{"given":"Stewart A.","family":"Factor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"11_CR1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","volume":"17","author":"MM Hoehn","year":"1967","unstructured":"Hoehn MM, Yahr MD: Parkinsonism: onset, progression, and mortality. Neurology 1967, 17:427\u2013442.","journal-title":"Neurology"},{"key":"11_CR2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJM196902132800701","volume":"280","author":"GC Cotzias","year":"1969","unstructured":"Cotzias GC, Papavasiliou PS, Gellene R: Modification of parkinsonism-chronic treatment with L-DOPA. N Engl J Med 1969, 280:337\u2013345.","journal-title":"N Engl J Med"},{"key":"11_CR3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/ana.410220103","volume":"21","author":"RC Duvoisin","year":"1987","unstructured":"Duvoisin RC: To treat early or to treat late? Ann Neurol 1987, 21:2\u20133.","journal-title":"Ann Neurol"},{"key":"11_CR4","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/archneur.1986.00520040080025","volume":"43","author":"E Melamed","year":"1986","unstructured":"Melamed E: Initiation of levodopa therapy in parkinsonian patients should be delayed until advanced stages of the disease. Arch Neurol 1986, 43:402\u2013405.","journal-title":"Arch Neurol"},{"key":"11_CR5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/archneur.1986.00520040083026","volume":"43","author":"CH Markham","year":"1986","unstructured":"Markham CH, Diamond SG: Modification of Parkinson\u2019s disease by long-term levodopa treatment. Arch Neurol 1986, 43:405\u2013407.","journal-title":"Arch Neurol"},{"key":"11_CR6","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/archneur.1986.00520040085027","volume":"43","author":"V Hachinski","year":"1986","unstructured":"Hachinski V: Timing of levodopa therapy. Arch Neurol 1986, 43:407.","journal-title":"Arch Neurol"},{"key":"11_CR7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/mds.870080302","volume":"8","author":"SA Factor","year":"1993","unstructured":"Factor SA, Weiner WJ: Early combination therapy with bromocriptine and levodopa in Parkinson\u2019s disease. Mov Disord 1993, 8:257\u2013262.","journal-title":"Mov Disord"},{"key":"11_CR8","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/1531-8257(199909)14:5<716::AID-MDS1002>3.0.CO;2-Q","volume":"14","author":"WJ Weiner","year":"1999","unstructured":"Weiner WJ: The initial treatment of Parkinson\u2019s disease should begin with levodopa. Mov Disord 1999, 14:716\u2013724.","journal-title":"Mov Disord"},{"key":"11_CR9","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/1531-8257(199909)14:5<725::AID-MDS1003>3.0.CO;2-L","volume":"14","author":"JL Montastruc","year":"1999","unstructured":"Montastruc JL, Rascol O, Senard J-M: Treatment of Parkinson\u2019s disease should begin with a dopamine agonist. Mov Disord 1999, 14:725\u2013730.","journal-title":"Mov Disord"},{"key":"11_CR10","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/1531-8257(200003)15:2<360::AID-MDS1033>3.0.CO;2-N","volume":"15","author":"SA Factor","year":"2000","unstructured":"Factor SA: The initial treatment of Parkinson\u2019s disease. Mov Disord 2000, 15:360\u2013361.","journal-title":"Mov Disord"},{"key":"11_CR11","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/jnnp.68.6.685","volume":"68","author":"DJ Brooks","year":"2000","unstructured":"Brooks DJ: Dopamine agonists: their role in the treatment of Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 2000, 68:685\u2013690.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"11_CR12","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1001\/archneur.57.3.406","volume":"57","author":"LM Shulman","year":"2000","unstructured":"Shulman LM: Levodopa toxicity in Parkinson\u2019s disease: reality or myth? Reality-practice patterns should change. Arch Neurol 2000, 57:406\u2013407.","journal-title":"Arch Neurol"},{"key":"11_CR13","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/archneur.57.3.408","volume":"57","author":"WJ Weiner","year":"2000","unstructured":"Weiner WJ: Is levodopa toxic? Arch Neurol 2000, 57:408\u2013410.","journal-title":"Arch Neurol"},{"key":"11_CR14","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/archneur.57.3.410","volume":"57","author":"V Hachinski","year":"2000","unstructured":"Hachinski V: Levodopa toxicity. Arch Neurol 2000, 57:410.","journal-title":"Arch Neurol"},{"key":"11_CR15","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1001\/jama.284.15.1971","volume":"284","author":"CM Tanner","year":"2000","unstructured":"Tanner CM: Dopamine agonists in early therapy for Parkinson\u2019s disease: Promise and problems. JAMA 2000, 284:1971\u20131973.","journal-title":"JAMA"},{"key":"11_CR16","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1212\/WNL.22.5_Part_2.22","volume":"22","author":"A Barbeau","year":"1972","unstructured":"Barbeau A: Long-term appraisal of levodopa therapy. Neurology 1972, 22(suppl):22\u201324.","journal-title":"Neurology"},{"key":"11_CR17","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1212\/WNL.29.9_Part_1.1253","volume":"29","author":"RP Lesser","year":"1979","unstructured":"Lesser RP, Fahn S, Snider SR, et al.: Analysis of the clinical problems in parkinsonism and the complications of long term therapy. Neurology 1979, 29:1253\u20131260.","journal-title":"Neurology"},{"key":"11_CR18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ana.410220104","volume":"22","author":"GJ Jong de","year":"1987","unstructured":"de Jong GJ, Meerwaldt JD, Schmitz PIM: Factors that influence the occurence of response variations in Parkinson\u2019s disease. Ann Neurol 1987, 22:4\u20137.","journal-title":"Ann Neurol"},{"key":"11_CR19","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1212\/WNL.41.5.622","volume":"41","author":"JM Cedarbaum","year":"1991","unstructured":"Cedarbaum JM, Gandy SE, McDowell FH: \"Early\" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesia or dementia in Parkinson\u2019s disease. Neurology 1991, 41:622\u2013629.","journal-title":"Neurology"},{"key":"11_CR20","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1212\/WNL.38.9.1410","volume":"38","author":"J Blin","year":"1988","unstructured":"Blin J, Bonnet A-M, Agid Y: Does Levodopa aggravate Parkinson\u2019s disease? Neurology 1988, 38:1410\u20131416.","journal-title":"Neurology"},{"key":"11_CR21","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1212\/WNL.41.3.380","volume":"41","author":"T Caraceni","year":"1991","unstructured":"Caraceni T, Scigliano G, Musicco M: The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa: role of early treatment and disease progression. Neurology 1991, 41:380\u2013384.","journal-title":"Neurology"},{"key":"11_CR22","first-page":"253","volume":"19","author":"MM Hoehn","year":"1983","unstructured":"Hoehn MM: Parkinsonism treated with levodopa: progression and mortality. J Neural Transm 1983, 19:253\u2013264.","journal-title":"J Neural Transm"},{"key":"11_CR23","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/jnnp.53.3.224","volume":"53","author":"MW Horstink","year":"1990","unstructured":"Horstink MW, Zijlmans JCM, Pasman JW, et al.: Severity of Parkinson\u2019s disease is a risk factor for peak dose dyskinesia. J Neurol Neurosurg Psychiatry 1990, 53:224\u2013226.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"11_CR24","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1212\/WNL.40.9.1344","volume":"40","author":"RAC Roos","year":"1990","unstructured":"Roos RAC, Vredevoogd CB, van der Velde EA: Response fluctuations in Parkinson\u2019s disease. Neurology 1990, 40:1344\u20131346.","journal-title":"Neurology"},{"key":"11_CR25","first-page":"A373","volume":"54","author":"VS Kostic","year":"2000","unstructured":"Kostic VS, Marinkovic J, Svetel M, et al.: The effect of stage of Parkinson\u2019s disease at the onset of levodopa therapy on development of motor complications. Neurology 2000, 54(suppl):A373.","journal-title":"Neurology"},{"key":"11_CR26","volume-title":"Parkinson\u2019s Disease: Diagnosis and Clinical Management","author":"JW Langston","year":"2001","unstructured":"Langston JW: The impact of MPTP on Parkinson\u2019s disease research: past, present and future. In Parkinson\u2019s Disease: Diagnosis and Clinical Management. Edited by Factor SA, Weiner WJ. New York: Demos; 2001:In press."},{"key":"11_CR27","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/ana.410430502","volume":"43","author":"S Fahn","year":"1998","unstructured":"Fahn S: Welcome news about levodopa, but uncertainty remains. Ann Neurol 1998, 43:551\u2013554.","journal-title":"Ann Neurol"},{"key":"11_CR28","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/ana.410240303","volume":"24","author":"G Fabbrini","year":"1988","unstructured":"Fabbrini G, Mouradian MM, Juncos JL, et al.: Motor fluctuations in Parkinson\u2019s disease: central pathophysiological mechanisms, part I.. Ann Neurol 1988, 24:366\u2013371.","journal-title":"Ann Neurol"},{"key":"11_CR29","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/ana.410080603","volume":"8","author":"E Melamed","year":"1980","unstructured":"Melamed E, Hefti F, Wurtman RJ: Nondopaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism. Ann Neurol 1980, 8:558\u2013563.","journal-title":"Ann Neurol"},{"key":"11_CR30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/ana.410360108","volume":"36","author":"D Bravi","year":"1994","unstructured":"Bravi D, Mouradian MM, Roberts JW, et al.: Wearing-off fluctuations in Parkinson\u2019s disease: contributions of postsynaptic mechanisms. Ann Neurol 1994, 36:27\u201331.","journal-title":"Ann Neurol"},{"key":"11_CR31","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/ana.410240304","volume":"24","author":"MM Mouradian","year":"1988","unstructured":"Mouradian MM, Juncos JL, Fabbrini G, et al.: Motor fluctuations in Parkinson\u2019s disease: central pathophysiological mechanisms, part II. Ann Neurol 1988, 24:372\u2013378.","journal-title":"Ann Neurol"},{"key":"11_CR32","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/ana.410270105","volume":"27","author":"MM Mouradian","year":"1990","unstructured":"Mouradian MM, Heuser JE, Baronti F, Chase TN: Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson\u2019s disease. Ann Neurol 1990, 27:18\u201323.","journal-title":"Ann Neurol"},{"key":"11_CR33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1212\/WNL.31.2.125","volume":"31","author":"CH Markham","year":"1981","unstructured":"Markham CH, Diamond SG: Evidence to support early levodopa therapy in Parkinson\u2019s disease. Neurology 1981, 31:125\u2013131.","journal-title":"Neurology"},{"key":"11_CR34","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/ana.410190410","volume":"19","author":"CH Markham","year":"1986","unstructured":"Markham CH, Diamond SG: Long-term follow-up of early dopa treatment in Parkinson\u2019s disease. Ann Neurol 1986, 19:365\u2013372.","journal-title":"Ann Neurol"},{"key":"11_CR35","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/ana.410320616","volume":"32","author":"S Fahn","year":"1992","unstructured":"Fahn S, Cohen G: The oxidant stress hypothesis in Parkinson\u2019s disease: evidence supporting it. Ann Neurol 1992, 32:804\u2013811.","journal-title":"Ann Neurol"},{"key":"11_CR36","first-page":"32","volume":"40","author":"CW Olanow","year":"1990","unstructured":"Olanow CW: Oxidation reactions in Parkinson\u2019s disease. Neurology 1990, 40(suppl):32\u201337.","journal-title":"Neurology"},{"key":"11_CR37","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/ana.410320615","volume":"32","author":"DB Calne","year":"1992","unstructured":"Calne DB: The free radical hypothesis in Parkinson\u2019s disease: evidence against it. Ann Neurol 1992, 32:799\u2013803.","journal-title":"Ann Neurol"},{"key":"11_CR38","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1212\/WNL.50.4.858","volume":"50","author":"Y Agid","year":"1998","unstructured":"Agid Y: Levodopa: is toxicity a myth? Neurology 1998, 50:858\u2013863.","journal-title":"Neurology"},{"key":"11_CR39","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0140-6736(05)70285-3","volume":"351","author":"Y Agid","year":"1998","unstructured":"Agid Y, Chase T, Marsden D: Adverse reactions to levodopa: drug toxicity or progression of disease? Lancet 1998, 351:851\u2013852.","journal-title":"Lancet"},{"key":"11_CR40","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/1531-8257(199911)14:6<911::AID-MDS1001>3.0.CO;2-H","volume":"14","author":"Y Agid","year":"1999","unstructured":"Agid Y, Ahlskog E, Albanese A, et al.: Levodopa in the treatment of Parkinson\u2019s disease: a consensus meeting. Mov Disord 1999, 14:911\u2013913.","journal-title":"Mov Disord"},{"key":"11_CR41","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1212\/WNL.47.6_Suppl_3.184S","volume":"47","author":"S Fahn","year":"1996","unstructured":"Fahn S: Is Levodopa toxic? Neurology 1996, 47(suppl):S184-S195.","journal-title":"Neurology"},{"key":"11_CR42","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0014-4886(90)90134-E","volume":"108","author":"JW Olney","year":"1990","unstructured":"Olney JW, Zorumski CF, Stewart GR, et al.: Excitotoxicity of L-DOPA and 6-OH-DOPA: implications for Parkinson\u2019s and Huntington\u2019s diseases. Exp Neurol 1990, 108:269\u2013272.","journal-title":"Exp Neurol"},{"key":"11_CR43","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ana.410340515","volume":"34","author":"S Przedborski","year":"1993","unstructured":"Przedborski S, Jackson-Lewis V, Muthane U, et al.: Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann Neurol 1993, 34:715\u2013723.","journal-title":"Ann Neurol"},{"key":"11_CR44","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/mds.870120105","volume":"12","author":"I Ziv","year":"1997","unstructured":"Ziv I, Zilkha-Falb R, Shirvan A, et al.: Levodopa induces apoptosis in cultured neuronal cells-a possible accelerator of nigrostriatal degeneration in Parkinson\u2019s disease? Mov Disord 1997, 12:17\u201323.","journal-title":"Mov Disord"},{"key":"11_CR45","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1212\/WNL.31.9.1194","volume":"31","author":"F Hefti","year":"1981","unstructured":"Hefti F, Melamed E, Bhawan J, Wurtman RJ: Long-term administration of levodopa does not damage dopaminergic neurons in the mouse. Neurology 1981, 31:1194\u20131195.","journal-title":"Neurology"},{"key":"11_CR46","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1471-4159.1984.tb12834.x","volume":"43","author":"TL Perry","year":"1984","unstructured":"Perry TL, Yong VW, Ito M, et al.: Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-dopa and carbidopa chronically. J Neurochem 1984, 43:990\u2013993.","journal-title":"J Neurochem"},{"key":"11_CR47","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1126\/science.850799","volume":"196","author":"GC Cotzias","year":"1977","unstructured":"Cotzias GC, Miller ST, Tang LC, Papavasiliou PS: Levodopa, fertility and longevity. Science 1977, 196:549\u2013551.","journal-title":"Science"},{"key":"11_CR48","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/mds.870080202","volume":"8","author":"SB Blunt","year":"1993","unstructured":"Blunt SB, Jenner P, Marsden CD: Suppressive effect of L-Dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov Disord 1993, 8:129\u2013133.","journal-title":"Mov Disord"},{"key":"11_CR49","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/ana.410430504","volume":"43","author":"MG Murer","year":"1998","unstructured":"Murer MG, Dziewczapolski G, Menalled, et al.: Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions.. Ann Neurol 1998, 43:561\u2013575.","journal-title":"Ann Neurol"},{"key":"11_CR50","first-page":"274","volume":"728","author":"T Fukuda","year":"1996","unstructured":"Fukuda T, Watabe K, Tanaka J: Effects of bromocriptine and\/or L-DOPA on neurons in substantia nigra of MPTP-treated C57BL\/6 mice. Brain Res 1996, 728:274\u2013276.","journal-title":"Brain Res"},{"key":"11_CR51","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/mds.870010109","volume":"1","author":"NP Quinn","year":"1986","unstructured":"Quinn NP, Parkes D, Janota I, Marsden CD: Case report: preservation of the substantia nigra and locus ceruleus in a patient receiving levodopa (2g) plus a decarboxylase inhibitor over a four-year period. Mov Disord 1986, 1:65\u201368.","journal-title":"Mov Disord"},{"key":"11_CR52","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/mds.870120503","volume":"12","author":"AH Rajput","year":"1997","unstructured":"Rajput AH, Fenton ME, Birdi S, Macaulay R: Is levodopa toxic to human substantia nigra? Mov Disord 1997, 12:634\u2013638.","journal-title":"Mov Disord"},{"key":"11_CR53","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1212\/WNL.22.5_Part_2.56","volume":"22","author":"MD Yahr","year":"1972","unstructured":"Yahr MD, Wolf A, Antunes J-L, et al.: Autopsy findings in parkinsonism following treatment with levodopa. Neurology 1972, 22(suppl):56\u201371.","journal-title":"Neurology"},{"key":"11_CR54","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/S0140-6736(99)01398-7","volume":"353","author":"K Gwinn-Hardy","year":"1999","unstructured":"Gwinn-Hardy K, Evidente VGH, Waters C, et al.: L-dopa slows the progression of familial parkinsonism. Lancet 1999, 353:1850\u20131851.","journal-title":"Lancet"},{"key":"11_CR55","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1001\/jama.284.15.1931","volume":"284","author":"Parkinson Study Group","year":"2000","unstructured":"Parkinson Study Group: Pramipexole vs levodopa as initial treatment for Parkinson\u2019s disease: a randomized controlled trial. JAMA 2000, 284:1931\u20131938. This is a 2 year, double-blind comparison of levodopa and pramipexole in early PD patients. It includes an imaging arm of the study.","journal-title":"JAMA"},{"key":"11_CR56","first-page":"A330","volume":"50","author":"JS Rakshi","year":"1998","unstructured":"Rakshi JS, Bailey DL, Uema T, et al.: Is ropinirole, a selective D2 receptor agonist, neuroprotective in early Parkinson\u2019s disease? A [18F]dopa PET study. Neurology 1998, 50(suppl):A330.","journal-title":"Neurology"},{"key":"11_CR57","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archneur.56.5.529","volume":"56","author":"S Fahn","year":"1999","unstructured":"Fahn S: Parkinson\u2019s disease: the effect of levodopa and the ELLDOPA trial. Arch Neurol 1999, 56:529\u2013535.","journal-title":"Arch Neurol"},{"key":"11_CR58","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1212\/WNL.49.1_Suppl_1.S2","volume":"49","author":"MB Stern","year":"1997","unstructured":"Stern MB: Contemporary approaches to the pharmacotherapeutic management of Parkinson\u2019s disease: an overview. Neurology 1997, 49(suppl):S2-S9.","journal-title":"Neurology"},{"key":"11_CR59","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1046\/j.1471-4159.1994.62031034.x","volume":"62","author":"T Yoshikawa","year":"1994","unstructured":"Yoshikawa T, Minamiyama Y, Naito Y, et al.: Antioxidant properties of bromocriptine, a dopamine agonist. J Neurochem 1994, 62:1034\u20131038.","journal-title":"J Neurochem"},{"key":"11_CR60","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF01273182","volume":"104","author":"PM Carvey","year":"1997","unstructured":"Carvey PM, Pieri S, Ling ZD: Attenuation of levodopainduced toxicity in mesencephalic cultures by pramipexole. J Neural Transm 1997, 104:209\u2013228.","journal-title":"J Neural Transm"},{"key":"11_CR61","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0197-4580(92)90048-3","volume":"13","author":"DL Felten","year":"1992","unstructured":"Felten DL, Felten SY, Fuller RW, et al.: Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged Fischer 344 rats. Neurobiol Aging 1992, 13:339\u2013351.","journal-title":"Neurobiol Aging"},{"key":"11_CR62","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0025-7125(05)70112-7","volume":"83","author":"SA Factor","year":"1999","unstructured":"Factor SA: Dopamine agonists. Med Clin N America 1999, 83:415\u2013443.","journal-title":"Med Clin N America"},{"key":"11_CR63","volume-title":"Parkinson\u2019s Disease: Diagnosis and Clinical Management","author":"T Simuni","year":"2001","unstructured":"Simuni T, Hurtig H: Levodopa: 30 years of progress. In Parkinson\u2019s Disease: Diagnosis and Clinical Management. Edited by Factor SA, Weiner WJ. New York: Demos; 2001:In press."},{"key":"11_CR64","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1212\/WNL.43.10.1918","volume":"43","author":"RJ Uitti","year":"1993","unstructured":"Uitti RJ, Ahlskog JE, Maraganore DM, et al.: Levodopa therapy and survival in idiopathic Parkinson\u2019s disease: Olmsted County project. Neurology 1993, 43:1918\u20131926. A population-based study examining mortality in PD patients.","journal-title":"Neurology"},{"key":"11_CR65","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ana.410220105","volume":"22","author":"SG Diamond","year":"1987","unstructured":"Diamond SG, Markham CH, Hoehn MM, et al.: Multicenter study of Parkinson mortality with early versus later dopa treatment. Ann Neurol 1987, 22:8\u201312.","journal-title":"Ann Neurol"},{"key":"11_CR66","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1212\/WNL.40.2.265","volume":"40","author":"G Scigliano","year":"1990","unstructured":"Scigliano G, Musicco M, Soliveri P, et al.: Mortality associated with early and late levodopa therapy initiation in Parkinson\u2019s disease. Neurology 1990. 40:265\u2013269.","journal-title":"Neurology"},{"key":"11_CR67","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/BF02220609","volume":"43","author":"H Przuntek","year":"1992","unstructured":"Przuntek H, Welzel D, Blummer E, et al.: Bromocriptine lessens the incidence of mortality in L-dopa treated parkinsonian patients: Prado study discontinued. Eur J Clin Pharmacol 1992, 43:357\u2013363.","journal-title":"Eur J Clin Pharmacol"},{"key":"11_CR68","doi-asserted-by":"crossref","first-page":"677","DOI":"10.7326\/0003-4819-83-5-677","volume":"83","author":"MD Yahr","year":"1975","unstructured":"Yahr MD: Levodopa. Ann Int Med 1975, 83:677\u2013682.","journal-title":"Ann Int Med"},{"key":"11_CR69","doi-asserted-by":"crossref","first-page":"456","DOI":"10.7326\/0003-4819-83-4-456","volume":"83","author":"RD Sweet","year":"1975","unstructured":"Sweet RD, McDowell FH: Five years\u2019 treatment of Parkinson\u2019s disease with levodopa: therapeutic results and survival of 100 patients. Ann Int Med 1975, 83:456\u2013463.","journal-title":"Ann Int Med"},{"key":"11_CR70","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1212\/WNL.34.8.991","volume":"34","author":"AH Rajput","year":"1984","unstructured":"Rajput AH, Stern W, Laverly WH: Chronic low-dose levodopa therapy in Parkinson\u2019s disease: an argument for delaying levodopa therapy. Neurology 1984, 34:991\u2013996.","journal-title":"Neurology"},{"key":"11_CR71","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1212\/WNL.36.11.1528","volume":"36","author":"WH Poewe","year":"1986","unstructured":"Poewe WH, Lees AJ, Stern GM: Low dose L-dopa therapy in Parkinson\u2019s disease: a 6-year follow-up study. Neurology 1986, 36:1528\u20131530.","journal-title":"Neurology"},{"key":"11_CR72","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1212\/WNL.53.5.1012","volume":"53","author":"WC Koller","year":"1999","unstructured":"Koller WC, Hutton JT, Tolosa E, et al.: Immediaterelease and controlled-release carbidopa\/levodopa in PD: a 5-year randomized multicenter study. Neurology 1999, 53:1012\u20131019. A 5-year double blind randomized comparison of standard preparation and controlled release forms of LD.","journal-title":"Neurology"},{"key":"11_CR73","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1212\/WNL.37.5.826","volume":"37","author":"UK Rinne","year":"1987","unstructured":"Rinne UK: Early combination of bromocriptine and levodopa in the treatment of Parkinson\u2019s disease: a 5-year follow-up. Neurology 1987, 37:826\u2013828.","journal-title":"Neurology"},{"key":"11_CR74","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1136\/jnnp.57.8.903","volume":"57","author":"MA Hely","year":"1994","unstructured":"Hely MA, Morris JGL, Reid WGJ, et al.: The Sidney Multicentre Study of Parkinson\u2019s disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 1994, 57:903\u2013910.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"11_CR75","first-page":"3","volume":"28","author":"T Nakanishi","year":"1988","unstructured":"Nakanishi T, Mizuno Y, Goto I, et al.: A nation-wide collaborative study on the long-term effects of bromocriptine in patients with Parkinson\u2019s disease: first interim report in Japan. Eur Neurol 1988, 28(suppl):3\u20138.","journal-title":"Eur Neurol"},{"key":"11_CR76","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/WNL.53.3.573","volume":"53","author":"P Barone","year":"1999","unstructured":"Barone P, Bravi D, Bermejo-Pareja F, et al.: Pergolide monotherapy in the treatment of early PD: a randomized, controlled study.. Neurology 1999, 53:573\u2013579. A 3-month, placebo-controlled, randomized, double blind trial of pergolide in early PD patients.","journal-title":"Neurology"},{"key":"11_CR77","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1212\/WNL.49.2.393","volume":"49","author":"CH Adler","year":"1997","unstructured":"Adler CH, Sethi KD, Hauser RA, et al.: Ropinirole for the treatment of early Parkinson\u2019s disease. Neurology 1997, 49:393\u2013399. A 6-month, placebo-controlled, randomized, double-blind, trial of ropinirole in early PD patients.","journal-title":"Neurology"},{"key":"11_CR78","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","volume":"342","author":"O Rascol","year":"2000","unstructured":"Rascol O, Brooks DJ, Korczyn AD, et al.: A five-year study of the incidence of dyskinesia in patients with early Parkinson\u2019s disease who were treated with ropinirole or levodopa. N Engl J Med 2000, 342:1484\u20131491. This is a 5-year, double blind comparison of levodopa and ropinirole in early PD patients.","journal-title":"N Engl J Med"},{"key":"11_CR79","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/mds.870130111","volume":"13","author":"O Rascol","year":"1998","unstructured":"Rascol O, Brooks DJ, Brunt ER, et al.: Ropinirole in the treatment of early Parkinson\u2019s disease: a 6-month interim report of a 5-year levodopa-controlled study. Mov Disord 1998, 13:39\u201345.","journal-title":"Mov Disord"},{"key":"11_CR80","first-page":"A89","volume":"54","author":"AD Korczyn","year":"2000","unstructured":"Korczyn AD, Keens J, Oldham M, Macrae S: The safety and efficacy of ropinirole as early therapy in elderly patients with Parkinson\u2019s disease. Neurology 2000, 54(suppl):A89.","journal-title":"Neurology"},{"key":"11_CR81","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1212\/WNL.49.3.724","volume":"49","author":"KM Shannon","year":"1997","unstructured":"Shannon KM, Bennett JP, Friedman JH, et al.: Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson\u2019s disease. Neurology 1997, 49:724\u2013728. A 6-month, placebo-controlled, randomized, double blind trial of pramipexole in early PD patients.","journal-title":"Neurology"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-001-0011-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-001-0011-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-001-0011-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:56:44Z","timestamp":1559437004000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-001-0011-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,11]]},"references-count":81,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2001,11]]}},"alternative-id":["11"],"URL":"https:\/\/doi.org\/10.1007\/s11940-001-0011-z","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,11]]}}}